370 related articles for article (PubMed ID: 20089172)
1. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells.
Gubbels JA; Felder M; Horibata S; Belisle JA; Kapur A; Holden H; Petrie S; Migneault M; Rancourt C; Connor JP; Patankar MS
Mol Cancer; 2010 Jan; 9():11. PubMed ID: 20089172
[TBL] [Abstract][Full Text] [Related]
2. MUC16 suppresses human and murine innate immune responses.
Felder M; Kapur A; Rakhmilevich AL; Qu X; Sondel PM; Gillies SD; Connor J; Patankar MS
Gynecol Oncol; 2019 Mar; 152(3):618-628. PubMed ID: 30626487
[TBL] [Abstract][Full Text] [Related]
3. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes.
Belisle JA; Horibata S; Jennifer GA; Petrie S; Kapur A; André S; Gabius HJ; Rancourt C; Connor J; Paulson JC; Patankar MS
Mol Cancer; 2010 May; 9():118. PubMed ID: 20497550
[TBL] [Abstract][Full Text] [Related]
4. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
5. Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells.
Lo Monaco E; Tremante E; Cerboni C; Melucci E; Sibilio L; Zingoni A; Nicotra MR; Natali PG; Giacomini P
Neoplasia; 2011 Sep; 13(9):822-30. PubMed ID: 21969815
[TBL] [Abstract][Full Text] [Related]
6. Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer.
Lakatos K; González G; Hoballah J; Brooker J; Jeong S; Evans C; Krauledat P; Hansen WP; Elias KM; Patankar M; Fülöp V; Konstantinopoulos PA; Cramer DW
J Ovarian Res; 2022 Feb; 15(1):28. PubMed ID: 35219339
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125).
Belisle JA; Gubbels JA; Raphael CA; Migneault M; Rancourt C; Connor JP; Patankar MS
Immunology; 2007 Nov; 122(3):418-29. PubMed ID: 17617155
[TBL] [Abstract][Full Text] [Related]
8. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells.
Koh J; Lee SB; Park H; Lee HJ; Cho NH; Kim J
Biochem Biophys Res Commun; 2012 Oct; 427(2):373-8. PubMed ID: 22995296
[TBL] [Abstract][Full Text] [Related]
10. Membrane nanotubes facilitate long-distance interactions between natural killer cells and target cells.
Chauveau A; Aucher A; Eissmann P; Vivier E; Davis DM
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5545-50. PubMed ID: 20212116
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway.
Le Maux Chansac B; Missé D; Richon C; Vergnon I; Kubin M; Soria JC; Moretta A; Chouaib S; Mami-Chouaib F
Int Immunol; 2008 Jul; 20(7):801-10. PubMed ID: 18441340
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity.
Labani-Motlagh A; Israelsson P; Ottander U; Lundin E; Nagaev I; Nagaeva O; Dehlin E; Baranov V; Mincheva-Nilsson L
Tumour Biol; 2016 Apr; 37(4):5455-66. PubMed ID: 26563374
[TBL] [Abstract][Full Text] [Related]
13. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.
Verhoeven DH; de Hooge AS; Mooiman EC; Santos SJ; ten Dam MM; Gelderblom H; Melief CJ; Hogendoorn PC; Egeler RM; van Tol MJ; Schilham MW; Lankester AC
Mol Immunol; 2008 Sep; 45(15):3917-25. PubMed ID: 18657862
[TBL] [Abstract][Full Text] [Related]
14. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
Mei JZ; Guo KY; Wei HM; Song CY
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
[TBL] [Abstract][Full Text] [Related]
15. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation.
Cebo C; Da Rocha S; Wittnebel S; Turhan AG; Abdelali J; Caillat-Zucman S; Bourhis JH; Chouaib S; Caignard A
J Immunol; 2006 Jan; 176(2):864-72. PubMed ID: 16393970
[TBL] [Abstract][Full Text] [Related]
16. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
[TBL] [Abstract][Full Text] [Related]
17. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.
Gubbels JA; Gadbaw B; Buhtoiarov IN; Horibata S; Kapur AK; Patel D; Hank JA; Gillies SD; Sondel PM; Patankar MS; Connor J
Cancer Immunol Immunother; 2011 Dec; 60(12):1789-800. PubMed ID: 21792658
[TBL] [Abstract][Full Text] [Related]
18. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.
Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G
Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020
[TBL] [Abstract][Full Text] [Related]
19. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
Crawford A; Haber L; Kelly MP; Vazzana K; Canova L; Ram P; Pawashe A; Finney J; Jalal S; Chiu D; Colleton CA; Garnova E; Makonnen S; Hickey C; Krueger P; DelFino F; Potocky T; Kuhnert J; Godin S; Retter MW; Duramad P; MacDonald D; Olson WC; Fairhurst J; Huang T; Martin J; Lin JC; Smith E; Thurston G; Kirshner JR
Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217340
[TBL] [Abstract][Full Text] [Related]
20. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]